Filing Details
- Accession Number:
- 0001209191-21-023006
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-25 16:27:15
- Reporting Period:
- 2021-03-23
- Accepted Time:
- 2021-03-25 16:27:15
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1789769 | Instil Bio Inc. | TIL | Biological Products, (No Disgnostic Substances) (2836) | 832072195 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1851041 | Bronson Crouch | C/O Instil Bio, Inc. 3963 Maple Avenue, Suite 350 Dallas TX 75219 | Ceo And Chairman | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-03-23 | 30,000,000 | $0.00 | 30,000,000 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2021-03-23 | 6,098,799 | $0.00 | 36,098,799 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2021-03-23 | 1,431,274 | $0.00 | 37,530,073 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2021-03-23 | 450,000 | $20.00 | 37,980,073 | No | 4 | P | Indirect | See footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See footnote |
| No | 4 | C | Indirect | See footnote |
| No | 4 | C | Indirect | See footnote |
| No | 4 | P | Indirect | See footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2021-03-23 | 25,000,000 | $0.00 | 30,000,000 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2021-03-23 | 5,082,333 | $0.00 | 6,098,799 | $0.00 |
| Common Stock | Series C Preferred Stock | Disposition | 2021-03-23 | 1,192,729 | $0.00 | 1,431,274 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 2,537,873 | Direct | |
| Common Stock | 2,399,999 | Indirect | See footnote |
Footnotes
- Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date.
- The securities are held by Curative Ventures V LLC (the "LLC"). CV-Immetacyte Ultimate Manager LLC ("Ultimate Manager") is the generalpartner of CV-Immetacyte Manager LP, the general partner of the LLC. The Reporting Person is the manager of Ultimate Manager and disclaimsSection 16 beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- The securities are held by SB2A LP. The Reporting Person is the manager of SB2A Management LLC, the general partner and manager ofSB2A LP.
Billionaire Hedge Funds
